Applied Genetic Tech (AGTC) Recent Earnings
Applied Genetic Tech (AGTC) reported a 2nd Quarter December 2019 loss of $0.47 per share on revenue of $2.5 million. The consensus estimate was a loss of $0.59 per share. Revenue fell 58.7% compared to the same quarter a year ago.
Applied Genetic Technologies Corp is a clinical-stage biotechnology company. It is primarily developing gene therapy products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology.